NASDAQ:RTRX - Retrophin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.01 +0.44 (+2.37 %)
(As of 05/20/2019 07:35 AM ET)
Previous Close$18.57
Today's Range$18.33 - $19.2750
52-Week Range$17.53 - $33.00
Volume483,510 shs
Average Volume459,510 shs
Market Capitalization$787.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$164.25 million
Book Value$6.90 per share

Profitability

Net Income$-102,680,000.00

Miscellaneous

Employees214
Market Cap$787.77 million
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.41. The biopharmaceutical company earned $39.57 million during the quarter, compared to analysts' expectations of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. Retrophin's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.14) EPS. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Retrophin.

What price target have analysts set for RTRX?

6 equities research analysts have issued 1-year target prices for Retrophin's shares. Their forecasts range from $36.00 to $57.00. On average, they expect Retrophin's stock price to reach $45.6667 in the next year. This suggests a possible upside of 140.2% from the stock's current price. View Analyst Price Targets for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

Has Retrophin been receiving favorable news coverage?

News headlines about RTRX stock have been trending positive on Monday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Retrophin earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Retrophin investors own include CVS Health (CVS), Gilead Sciences (GILD), Celgene (CELG), Intercept Pharmaceuticals (ICPT), bluebird bio (BLUE), GW Pharmaceuticals PLC- (GWPH), Horizon Therapeutics (HZNP), Incyte (INCY), Novavax (NVAX) and Omeros (OMER).

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
  • Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)

Who are Retrophin's major shareholders?

Retrophin's stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.37%), Perceptive Advisors LLC (7.37%), Macquarie Group Ltd. (6.03%), The Manufacturers Life Insurance Company (4.69%), Dimensional Fund Advisors LP (2.93%) and Geode Capital Management LLC (1.29%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which major investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Perceptive Advisors LLC, Perceptive Advisors LLC, Northern Trust Corp, PNC Financial Services Group Inc., Schonfeld Strategic Advisors LLC, First Trust Advisors LP and Oak Ridge Investments LLC. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.

Which major investors are buying Retrophin stock?

RTRX stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Opaleye Management Inc., J. Goldman & Co LP, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., The Manufacturers Life Insurance Company , Dimensional Fund Advisors LP and Geode Capital Management LLC. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $19.01.

How big of a company is Retrophin?

Retrophin has a market capitalization of $787.77 million and generates $164.25 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Retrophin employs 214 workers across the globe.

What is Retrophin's official website?

The official website for Retrophin is http://www.retrophin.com.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  563
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel